Magenta Therapeutics, Inc. (MGTA) Stock

About Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials. Additionally, the company is developing a CD45-antibody drug conjugate, designed to target both HSCs and immune cells. This asset is in investigational new drug (IND) enabling studies, exploring its potential as a monotherapy for autoimmune diseases and in hematology-oncology transplant settings. Another therapeutic, MGTA-145, is undergoing Phase II clinical evaluation for its application in both autologous and allogeneic transplant procedures. Beyond these, Magenta boasts a cell therapy initiative featuring E478, a small molecule aryl hydrocarbon receptor antagonist, which is being explored for stem cell-based gene therapy and genome editing. The company actively engages in strategic alliances, including a research and clinical collaboration with AVROBIO, Inc. focused on treating lysosomal storage disorders. Furthermore, it partners with Beam Therapeutics, Inc. to investigate the utility of MGTA-117 as a conditioning regimen for patients with sickle cell disease and beta-thalassemia. Originally incorporated in 2015 as HSCTCo Therapeutics, Inc., the company adopted its current name, Magenta Therapeutics, Inc., in February 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.

Magenta Therapeutics, Inc. is headquartered in US.

Magenta Therapeutics, Inc. (MGTA) stock trades at $0.70 with a market capitalization of $42.44M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.09, price-to-sales of 48.62. Over the past 52 weeks the stock has ranged between $0.32 and $1.81, and currently trades 61.3% below its 52-week high.

On profitability, Magenta Therapeutics, Inc. generates a return on equity (ROE) of -27.30%, return on capital employed of -15.83%, an operating margin of -8900.00%, a net profit margin of -8100.00%.

Official website: www.magentatx.com